The Role and Therapeutic Potential of Non-coding RNAs in Resistance to EGFR - TKIs Targeted Therapy for Non-small...

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Lung cancer, particularly non-small cell lung cancer (NSCLC), is a leading cause of cancer mortality globally.
• Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are standard treatments for NSCLC but often face acquired drug resistance.
• Overcoming EGFR-TKI resistance is a critical unmet need in NSCLC management.

Purpose of the Study:

• To review the role of non-coding RNAs (ncRNAs) in the development of resistance to EGFR-TKIs in NSCLC.
• To elucidate the underlying molecular mechanisms by which ncRNAs mediate EGFR-TKI resistance in NSCLC.

Main Methods:

• This study is a comprehensive review of existing literature on ncRNAs and EGFR-TKI resistance in NSCLC.
• Analysis focuses on ncRNA involvement in cellular drug efflux, epithelial-mesenchymal transition, apoptosis, autophagy, and EGFR mutations.

Main Results:

• Non-coding RNAs (ncRNAs) significantly contribute to NSCLC resistance against EGFR-TKIs.
• Mechanisms include modulation of drug efflux pumps, promotion of epithelial-mesenchymal transition, regulation of apoptosis and autophagy, and influence on EGFR mutation status.
• ncRNAs are identified as crucial mediators in the complex landscape of EGFR-TKI resistance.

Conclusions:

• Non-coding RNAs (ncRNAs) are pivotal in mediating non-small cell lung cancer (NSCLC) resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs).
• Targeting ncRNAs presents a promising therapeutic strategy to overcome or reverse EGFR-TKI resistance.
• Further research into ncRNA functions may offer new avenues for improving NSCLC treatment outcomes and patient prognosis.